1. Scrip
  2. >>Business

AZ names Steve Twait VP, alliance and integration

 
• By Lucie Ellis-Taitt

Steve Twait has joined AstraZeneca's business development leadership team in a newly created role – vice-president of alliance and integration management. Mr Twait joins AstraZeneca from Eli Lilly's alliance management and M&A integration group, where he founded the Office of Alliance Management. At Lilly he played a leading role in the integration of global partnerships with Bristol-Myers Squibb, Boehringer Ingelheim, and Daiichi Sankyo. Mr Twait will be based at the company's Cambridge, UK site.

Steve Twait has joined AstraZeneca's business development leadership team in a newly created role – vice-president of alliance and integration management. Mr Twait joins AstraZeneca from Eli Lilly's alliance management and M&A integration group, where he founded the Office of Alliance Management. At Lilly he played a leading role in the integration of global partnerships with Bristol-Myers Squibb, Boehringer Ingelheim, and Daiichi Sankyo. Mr Twait will be based at the company's Cambridge, UK site.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.

BIO Notebook: Policy Problems, ACIP’s Future, BI Is Popular, Makary On FDA-Industry Ties

 
• By Sarah Karlin-Smith and Mandy Jackson

Highlights from Day Two of the BIO International Convention include BIO officials raising concerns about Trump Administration policies, the future of ACIP, an interview with BI's head of global business development, and FDA Commissioner Martin Makary's view of the FDA-industry relationship.

Lilly Agrees To Acquire PCSK9 Base-Editing Partner Verve

 
• By Joseph Haas

Instead of opting in on Phase II-ready PCSK9-targeted VERVE-102, Lilly will buy its partner for up to $1.3bn. Analysts call the deal a bargain for Lilly, but fair to Verve.

Stock Watch: Generics Firms Trapped Between US Tariffs And European Austerity

 
• By Andy Smith

Successive annual reductions in European drug prices following the pandemic are affecting the global sales of generic pharmaceutical companies. Additionally, the imposition of US import tariffs may result in generic drug supply becoming unprofitable.

More from Scrip

Enliven Raises $230m To Fund Scemblix Leukemia Challenger

 
• By Andrew McConaghie

The company believes its drug could eventually displace Novartis’s Scemblix in first-line chronic myeloid leukemia treatment, but for now is preparing for a second-/third-line pivotal study.

Stock Watch: Generics Firms Trapped Between US Tariffs And European Austerity

 
• By Andy Smith

Successive annual reductions in European drug prices following the pandemic are affecting the global sales of generic pharmaceutical companies. Additionally, the imposition of US import tariffs may result in generic drug supply becoming unprofitable.

Innovent Builds Metabolic Pipeline While Retaining Oncology Backbone

 
• By Xu Hu

Innovent presented data on multiple pipeline assets at ASCO, including promising OS results for its first-in-class anti-PD-1/IL-2α-bias bispecific. The Chinese firm is also continuing to build out its metabolic disease portfolio and consider its partnering strategies, its CEO tells Scrip.